Background {#Sec1}
==========

Multiple sclerosis (MS) is a chronic and demyelinating disorder of the brain and spinal cord that mainly develops in young individuals \[[@CR1], [@CR2]\]. Tissue damage in MS results from a dynamic and complex interaction between the glia (oligodendrocytes and their precursors, astrocytes, and microglia), neurons, and immune system. Although there is an argument about whether the original cause of MS is extrinsic or intrinsic to the CNS, several researches in animal models in combination with evaluation of immune cells in humans have elucidated a fundamental function for adaptive immunity \[[@CR3], [@CR4]\]. It has been demonstrated that genetic and environmental factors play important roles in susceptibility to the disease \[[@CR5]\]. Vitamin D is a group of fat-soluble secosteroids that have functional and regulatory effects in the body. Vitamin D has been implicated in the development of the brain and spinal cord. Alternatively, the active form of vitamin D, 1,25-dihydroxyvitamin D has a wide anti-inflammatory and immunomodulatory properties \[[@CR6], [@CR7]\]. Vitamin D exerts its immunomodulatory functions within the immune system by decreasing the presentation of major histocompatibility complex (MHC) II on T cells and monocytes. Vitamin D also reduces T cell proliferation and pro-inflammatory cytokine release \[[@CR8]\]. The lower serum vitamin D levels compared to healthy controls have been reported in MS patients. Moreover, Vitamin D has positive effects in regulating MS risk development \[[@CR9], [@CR10]\]. The effects of Vitamin D on the immune system are exerted by binding to the nuclear Vitamin D Receptor (VDR) \[[@CR11]\]. Particular variants of the VDR gene are related to changes in vitamin D metabolism and function \[[@CR12]\]. Taken together, these results suggested that VDR may play an important role in the pathogenesis of MS.

The human *VDR* gene is located on the chromosome 12q12--14 and series of restriction fragment length polymorphisms (RFLP) in the human *VDR* gene have been reported, containing BsmI (rs1544410), ApaI (rs7975232), FokI (rs2228570), and TaqI (rs731236) restriction sites \[[@CR13]\]. ApaI, BsmI, and TaqI are localized near the 3′-untranslated region (UTR) of the *VDR* gene in the intron between exons 8 and 9, and shown to be in strong linkage disequilibrium (LD) with each other \[[@CR14]\]. The 3′-UTR of the *VDR* gene is involved in the regulation of gene expression by regulating the mRNA stability and expression level \[[@CR15]\]. Polymorphism FokI is located at the translation starting codon \[[@CR16]\].

The association between MS and *VDR* gene single nucleotide polymorphisms (SNPs) has been investigated in several studies. Particularly, studies have evaluated associations between the most common SNPs of the *VDR* gene (TaqI, ApaI, FokI, and BsmI polymorphisms) and MS. While studies in Australia \[[@CR17]\], Kuwait \[[@CR18]\], and southeast of Iran \[[@CR19]\] reported a significant association between TaqI, ApaI, and FokI polymorphisms and MS, other studies in Tunisia \[[@CR20]\], Slovakia \[[@CR21]\], and Greece \[[@CR22]\] have failed to find such association. The reasons for this disparity may be small sample sizes, low statistical power, clinical heterogeneity, or a combination of these factors. To offset these limitations, this meta-analysis was performed to investigate whether VDR gene polymorphisms contribute to MS or not. Up to now, there are four meta-analysis which investigated the association between VDR polymorphisms and MS. The two studies performed by Huang et al. \[[@CR23]\]., and Garcia-Martin et al. \[[@CR24]\]. have indicated that there was no association between *VDR* gene polymorphism and MS risk. Nevertheless, the other meta-analysis by Zhang et al. \[[@CR25]\]., and Tizaoui et al. \[[@CR26]\]. demonstrated a significant association between ApaI and FokI and MS susceptibility. Since publishing of the last meta-analysis, seven new studies have been founded in electronic databases. Therefore, we conducted a meta-analysis of all eligible published case-control studies to obtain an exact evaluation of the association between *VDR* gene polymorphisms and susceptibility to MS.

Methods {#Sec2}
=======

The current systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@CR27]\].

Publication search {#Sec3}
------------------

All relevant studies reporting the association between the *VDR* gene FokI (rs2228570) or/and TaqI (rs731236) or/and BsmI (rs1544410) or/and ApaI (rs7975232) polymorphisms and susceptibility to MS published up to May 2019 were identified by comprehensive systematic search in the electronic database of web of science, Scopus, and PubMed. The following search terms were applied: (VDR" or "vitamin D receptor") AND ("multiple sclerosis" OR "MS") AND ("polymorphisms" OR "single nucleotide" OR "polymorphism" OR "SNP" OR "variation" OR "mutation"). As a complementary approach, in order to detect additional potentially relevant studies, manual evaluation of the reference list of the included eligible studies was performed. In this meta-analysis, the strategy of search was restricted solely to the English-language publications and human population.

Study selection {#Sec4}
---------------

Two reviewers independently assessed titles and abstract of all studies retrieved in the initial search. Articles not following the eligibility criteria were excluded by applying a hierarchical approach based on study design. Full-text examination was applied if we could not decide include or exclude based on titles and abstract. In particular conditions, if an author has published more than one study by the same case series, the most recently published study was included. Any disagreements were discussed and resolved by consensus.

Eligibility criteria {#Sec5}
--------------------

Studies considered eligible if meet the following criteria: 1) All eligible case--control studies that evaluate the relationship between the *VDR* gene single nucleotide polymorphisms and the risk of MS as the main outcome; 2) Sufficient data are available to extract or calculate odds ratios (ORs) and 95% confidence intervals (CI); 3) Contained genotypic or allelic distributions of case and healthy individuals for *VDR* gene polymorphism in the studies. The exclusion criteria were as follows: 1) Studies which genotype or allelic frequency could not be extracted; 2) Letters, case reports, reviews, comments, book chapter, and abstracts; 3) Duplicated reports and studies with repetitive subjects. The application of these criteria yielded 30 case--control studies eligible for the meta-analysis.

Data extraction {#Sec6}
---------------

Two reviewers independently extracted all data according to standardized extraction form for the following data: The author's name, journal and year of publication, country of origin, ethnicity, number of cases and controls for every gender separately, mean or range of age, genotyping method, total sample size of cases and controls, and the number of cases and controls for each genotype. For quality assessment of the included publications, the Newcastle-Ottawa Scale (NOS) was applied \[[@CR28]\]. Studies with scores 0--3, 4--6 or 7--9 were of low, moderate or high-quality, respectively.

Statistical analysis {#Sec7}
--------------------

Deviation from Hardy--Weinberg equilibrium (HWE) for distribution of the allele frequencies was analyzed using Chi-Square test in control group. Sensitivity analysis was conducted to estimate the stability of the results by removing the studies not in HWE. The strength of association between the *VDR* gene FokI, TaqI, BsmI, and ApaI polymorphisms and susceptibility to MS was evaluated by OR and 95% CI. Defined model for FokI, TaqI, BsmI, ApaI were as follow, respectively: **FokI**; dominant model (ff + Ff vs. FF), recessive model (ff vs. Ff + FF), allelic model (f vs. F), homozygote model (ff vs. FF), and heterozygote model (Ff vs. FF); **TaqI**; dominant model (tt + Tt vs. TT), recessive model (tt vs. Tt + TT), allelic model (t vs. T), homozygote model (tt vs. TT), and heterozygote model (Tt vs. TT); **BsmI**; dominant model (bb + Bb vs. BB), recessive model (bb vs. Bb + BB), allelic model (b vs. B), homozygote model (bb vs. BB), and heterozygote model (Bb vs. BB); **ApaI**; dominant model (aa+Aa vs. AA), recessive model (aa vs. Aa+AA), allelic model (a vs. A), homozygote model (aa vs. AA), and heterozygote model (Aa vs. AA). For each genetic model, subgroup analysis was applied to evaluate ethnicity effects. In consideration of the possibility of heterogeneity (between study variability) across included studies, chi-square based Q-test was used \[[@CR29]\]. Additionally, to show possible heterogeneity quantitatively, the other index (*I*^*2*^) was calculated as the percentage of heterogeneity. There was significant heterogeneity if an *I*^*2*^ values exceeded 50% or the Q statistic had a *P* value less than 0.1. In the presence of significant heterogeneity, the random effects model (DerSimonian--Laird approach) was performed. Otherwise, the fixed effects model (Mantel--Haenszel approach) was performed for combination of data \[[@CR30], [@CR31]\]. Visual inspection of asymmetry in funnel plots asymmetry, Begg's test, and Egger's test were conducted to evaluate publication bias (*P* value\< 0.05 was considered statistically significant) \[[@CR32], [@CR33]\]. The data analyses were carried out using STATA (version 14.0; Stata Corporation, College Station, TX) and SPSS (version 23.0; SPSS, Inc. Chicago, IL).

Results {#Sec8}
=======

Study characteristics {#Sec9}
---------------------

The primary search in web of science, Scopus, and PubMed databases yielded a total of 636 publications. After removal of duplicates and evaluation of title/abstract, only 76 studies remained for full-text examination. Eventually, 30 studies met the inclusion criteria and included for quantitative synthesis. The search workflow is shown in Fig. [1](#Fig1){ref-type="fig"}. Study characteristics are summarized in Table [1](#Tab1){ref-type="table"}. Among 30 eligible studies, 16 Studies investigated FokI SNP, 23 Studies TaqI SNP, 16 studies BsmI SNP and 20 Studies ApaI SNP. The studies were published between 1999 and 2019. Taq-Man and PCR-RFLP genotyping methods were used by the most studies. Fig. 1Flow diagram of study selection process Table 1Characteristics of studies included in Meta-analysis of overall MSStudy authorYearCountryEthnicitySex cases/controlsTotal cases/controlAge case/control (Mean)Genotyping methodQuality scoreFokI (rs2228570) Partridge et al.2004UKEuropeanM = NR F=NR406 /23443.8 ± 11.2 / 50.1NR7 Tajouri et al.2005AustraliaAustralianM = NR F=NR98 / 93NRPCR--RFLP6  Smolders et al.2009NetherlandEuropeanM = 62/ 142 F = 150/ 147212 / 28946.7 ± 11.9 /34.9 ± 14.3PCR--RFLP8 Dickinson et al.2009AustraliaAustralianM = NR F=NR136 / 23543.5 ± 9.3/ 43.6 ± 9.2Taq-Man7 Simon et al.2010USAAmericanM = NR F=NR100 / 100NRTaq-Man7 Garcia-Martin et al.2013SpainEuropeanM = 94/ 98 F = 209/ 212303 / 31043.9 ± 11.4/ 43.4 ± 11.7Taq-Man8 Al-Temaimi et al.2015KuwaitAsianM = 17/ 19 F = 33/ 3150 / 5033.4 ± 9.6/ 28.6 ± 7.9Taq-Man7 Narooie-Nejad et al.2015IranAsianM = 25 / 28 F = 88/ 94113 / 12232.4 ± 8.9/ 30.8 ± 10.2PCR--RFLP7 Cierny et al.2015SlovakiaEuropeanM = 66 / 74 F = 204 / 229270 / 30341.3 ± 10.8/ 38.7 ± 13.6PCR--RFLP8 Luisa Agnello et al.2016ItalyEuropeanM = 24 / 30 F = 80 / 42104 / 7539.6 ± 10.3/ 45.2 ± 9.36PCR--RFLP6 Abdollahzadeh et al.2016IranAsianM = 40 / 38 F = 120 / 112160 / 15035.9 ± 3 / 36.8 ± 1.8PCR--RFLP7 Yucel et al.2017TurkeyEuropeanM = NRF=NR29 / 11433.7 ± 10.7 / 33.1 ± 8.5Taq-Man6 Bettencourt et al.2017PortugalEuropeanM = 185/198 F = 348/248533 / 44630.2 ± 9.3/ NRTaq-Man8 Kamisli et al.2018TurkeyEuropeanM = 46 / 58 F = 121 / 88167 / 14639.96 ± 9.4 / 33.81 ± 7.1Taq-Man7 Sadeghi et al.2018IranAsianM = 17/11 F = 63/3980 / 5018--60/ 18--60PCR--RFLP6 Křenek et al.2018Czech RepublicEuropeanM = 80/49 F = 216/86296/13534--37 / NRPCR--RFLP7TaqI (rs731236) Partridge et al.2004UKEuropeanM = NR F=NR402 /23143.8 ± 11.2 / 50.1NR7 Tajouri et al.2005AustraliaAustralianM = NR F=NR104 / 186NRPCR--RFLP6 Smolders et al.2009NetherlandEuropeanM = 62/ 142 F = 150/ 147212 / 28946.7 ± 11.9 /34.9 ± 14.3PCR--RFLP8 Dickinson et al.2009AustraliaAustralianM = NR F=NR136 / 23543.5 ± 9.3/ 43.6 ± 9.2Taq-Man7 Simon et al.2010USAAmericanM = NR F=NR100 / 100NRTaq-Man7 Sioka et al.2011GreeceEuropeanM = 23/ 23 F = 46/ 5869 / 8139 ± 10.5/38.7 ± 10.7Taq-Man7 Agliardi et al.2011ItalyEuropeanM = NR F=NR641 / 55827.8 ± 9.2/ 29.4 ± 6.5Taq-Man8 Irizar et al.2012SpainEuropeanM = NR F=NR136 / 33744.14 ± 13.02/ 50.17 ± 13.26PCR-SSP7 Garcia-Martin et al.2013SpainEuropeanM = 94/ 98 F = 209/ 212303 / 31043.9 ± 11.4/ 43.4 ± 11.7Taq-Man8 Selma et al.2015TunisiaAfricanM = 22/ 47 F = 38/ 6760 / 11435.8 ± 6.3 / 37 ± 9.3PCR--RFLP6 Narooie-Nejad et al.2015IranAsianM = 25 / 28 F = 88/ 94113 / 12232.4 ± 8.9/ 30.8 ± 10.2PCR--RFLP7 Al-Temaimi et al.2015KuwaitAsianM = 17/ 19 F = 33/ 3150 / 5033.4 ± 9.6/ 28.6 ± 7.9Taq-Man7 Yamout et al.2016LebanonAsianM = NR F=NR50 / 9932.3 ± 12.7 / 35.2 ± 13PCR--RFLP6 Cierny et al.2016SlovakiaEuropeanM = 66 / 74 F = 204 / 229270 / 30341.3 ± 10.8/ 38.7 ± 13.6PCR--RFLP8 Luisa Agnello et al.2016ItalyEuropeanM = 24 / 30 F = 80 / 42104 / 7539.6 ± 10.3/ 45.2 ± 9.36PCR--RFLP6 Terzi et al.2016TurkeyEuropeanM = NR F=NR87 / 9930.14 9.66/ NRPCR--RFLP6 Abdollahzadeh et al.2016IranAsianM = 40 / 38 F = 120 / 112160 / 15035.9 ± 3 / 36.8 ± 1.8PCR--RFLP7 Yucel et al.2017TurkeyEuropeanM = NR F=NR28 / 7233.7 ± 10.7 / 33.1 ± 8.5Taq-Man6 Kamisli et al.2018TurkeyEuropeanM = 46 / 58 F = 121 / 88167 / 14639.96 ± 9.4 / 33.81 ± 7.1Taq-Man7 Morales et al.2018MexicoAmericanM = 39/ 57 F = 81/123120 / 18033.89 ± 10.03/ 32.79 ± 10.17Taq-Man6 Sadeghi et al.2018IranAsianM = 17/11 F = 63/3980 / 5018--60/ 18--60PCR--RFLP6 Cakina et al..2018TurkeyEuropeanM = 19/22 F = 51/4870 / 7044.4 ± 11.2 / 38.2 ± 9.5PCR--RFLP7 Křenek et al.2018Czech RepublicEuropeanM = 80/49 F = 216/86296 / 13534--37 / NRPCR--RFLP7BsmI (rs1544410) Fukazawa et al.1999JapanAsianM = 21/33 F = 56/6277 / 9534.9 ± 12.9/NRPCR--RFLP8 Qinli Sun et al.2004ChinaAsianM = NR F=NR63 / 95NRPCR--RFLP6 Bing Wu et al.2009ChinaAsianM = NR F=NR83 / 120NRPCR--RFLP7 Simon et al.2010USAAmericanM = NR F=NR101 / 100NRTaq-Man7 Sioka et al.2011GreeceEuropeanM = 23/ 23 F = 46/ 5869 / 8139 ± 10.5/38.7 ± 10.7Taq-Man7 Al-Temaimi et al.2015KuwaitAsianM = 17/ 19 F = 33/ 3150 / 5033.4 ± 9.6/ 28.6 ± 7.9Taq-Man7 Narooie-Nejad et al.2015IranAsianM = 25 / 28 F = 88/ 94113 / 12232.4 ± 8.9/ 30.8 ± 10.2PCR--RFLP7 Abdollahzadeh et al.2016IranAsianM = 40 / 38 F = 120 / 112160 / 15035.9 ± 3 / 36.8 ± 1.8PCR--RFLP7 Yamout et al.2016LebanonAsianM = NR F=NR50 / 9932.3 ± 12.7 / 35.2 ± 13PCR--RFLP6 Cierny et al.2016SlovakiaEuropeanM = 66 / 74 F = 204 / 229270 / 30341.3 ± 10.8/ 38.7 ± 13.6PCR--RFLP8 Luisa Agnello et al.2016ItalyEuropeanM = 24 / 30 F = 80 / 42104 / 7539.6 ± 10.3/ 45.2 ± 9.36PCR--RFLP6 Terzi et al.2016TurkeyEuropeanM = NR F=NR87 / 10030.14 ± 9.66/ NRPCR--RFLP6 Morales et al.2017MexicoAmericanM = 39/ 57 F = 81/123120 / 18033.89 ± 10.03/ 32.79 ± 10.17Taq-Man6 Sadeghi et al.2018IranAsianM = 17/11 F = 63/3980 / 5018--60/ 18--60PCR--RFLP6 Cakina et al..2018TurkeyEuropeanM = 19/22 F = 51/4870 / 7044.4 ± 11.2 / 38.2 ± 9.5PCR--RFLP7 Křenek et al.2018Czech RepublicEuropeanM = 80/49 F = 216/86296 / 13534--37 / NRPCR--RFLP7ApaI (rs7975232) Niino et al.2000JapanAsianM = 21 / 33 F = 56 / 6277 / 9536.2 ± 11.2 / 34.4 ± 10.2PCR--RFLP7 Qinli Sun et al.2004ChinaAsianM = NR F=NR63 / 95NRPCR--RFLP6 Tajouri et al.2005AustraliaAustralianM = NR F=NR104 / 100NRPCR--RFLP6 Smolders et al.2009NetherlandEuropeanM = 62/ 142 F = 150/ 147212 / 28946.7 ± 11.9 /34.9 ± 14.3PCR--RFLP8 Bing Wu et al.2009ChinaAsianM = NR F=NR83 / 120NRPCR--RFLP7 Simon et al.2010USAAmericanM = NR F=NR100 / 100NRTaq-Man7Irizar et al.2012SpainEuropeanM = NR F=NR134 / 34044.14 ± 13.02/ 50.17 ± 13.26PCR-SSP7 Narooie-Nejad et al.2015IranAsianM = 25 / 28 F = 88/ 94113 / 12232.4 ± 8.9/ 30.8 ± 10.2PCR--RFLP7 Al-Temaimi et al.2015KuwaitAsianM = 17/ 19 F = 33/ 3150 / 5033.4 ± 9.6/ 28.6 ± 7.9Taq-Man7 Selma et al.2015TunisiaAfricanM = 22/ 47 F = 38/ 6760 / 11435.8 ± 6.3 / 37 ± 9.3PCR--RFLP6 Yamout et al.2016LebanonAsianM = NR F=NR50 / 13432.3 ± 12.7 / 35.2 ± 13PCR--RFLP6 Luisa Agnello et al.2016ItalyEuropeanM = 24 / 30 F = 80 / 42104 / 7539.6 ± 10.3/ 45.2 ± 9.36PCR--RFLP6 Abdollahzadeh et al.2016IranAsianM = 40 / 38 F = 120 / 112160 / 15035.9 ± 3 / 36.8 ± 1.8PCR--RFLP7 Cierny et al.2016SlovakiaEuropeanM = 66 / 74 F = 204 / 229270 / 30341.3 ± 10.8/ 38.7 ± 13.6PCR--RFLP8 Terzi et al.2016TurkeyEuropeanM = NR F=NR87 / 10030.14 9.66/ NRPCR--RFLP6 Yucel et al.2017TurkeyEuropeanM = NR F=NR26 / 8133.7 ± 10.7 / 33.1 ± 8.5Taq-Man6 Kamisli et al.2018TurkeyEuropeanM = 46 / 58 F = 121 / 88167 / 14639.96 ± 9.4 / 33.81 ± 7.1Taq-Man8 Sadeghi et al.2018IranAsianM = 17/11 F = 63/3980 / 5018--60/ 18--60PCR--RFLP7 Cakina et al..2018TurkeyEuropeanM = 19/22 F = 51/4870 / 7044.4 ± 11.2 / 38.2 ± 9.5PCR--RFLP7 Křenek et al.2018Czech RepublicEuropeanM = 80/49 F = 216/86296 / 13534--37 / NRPCR--RFLP7*NR* not reported, *M* male, *F* female, *MS* Multiple Sclerosis

Quantitative synthesis {#Sec10}
----------------------

The distributions of FokI, TaqI, BsmI and ApaI genotypes of the included studies are shown in Table [2](#Tab2){ref-type="table"}. FF for FokI SNP, TT for TaqI SNP, BB for BsmI SNP and AA for ApaI were used as the reference category. The heterogeneities in the comparisons (*I*^*2*^ \< 50%, fixed-effects models; *I*^*2*^ \> 50%, random-effects models) ascertained the application of Fixed-effects or random-effects models. Table 2Distribution of genotype and allele among MS patients and controlsStudy authorMS casesHealthy controlP-HWEMAFFFFfffFfFFFfFfFfFokI (rs2228570) Partridge et al.1551965550630683105462711970/220/42 Tajouri et al.47401113462344811116700/330/376 Smolders et al.7910330261163113134423602180/820/377 Dickinson et al.5861171779586110392821880/720/4 Simon et al.36451911783414415126740/570/37 Garcia-Martin et al.13014132401205144124424122080/070/335 Al-Temaimi et al.3314380203316182180/550/18 Narooie-Nejad et al.733281784893290215290/130/118 Cierny et al.9614331335205118143423792270/890/374 Luisa Agnello et al.3452181208829361094560/820/373 Abdollahzadeh et al.14677995225115980812190/970/73 Yucel et al.226150872348178500/160/219 Bettencourt et al.22322783673393204197456052870/790/321 Kamisli et al.75771522710794466234580/920/198 Sadeghi et al.47321126342026466340/260/34 Křenek et al.102145493492433774241481220/210/451Study authorMS casesHealthy controlP-HWEMAFTTTtttTtTTTtttTTTaqI (rs731236) Partridge et al.1402035948332186106392781840/510/398 Tajouri et al.2757201119710442402501220/570/327 Smolders et al.839633262162112138393622160/530/373 Dickinson et al.52681617210086108412801900/480/4 Simon et al.405010130703648161208010/4 Sioka et al.303099048333612102600/670/37 Agliardi et al.219308114746536220249896894270/190/375 Irizar et al.55701118092145157354472270/430/336 Garcia-Martin et al.12912945387219131144354062140/620/345 Selma et al.28293853575381188400/10/175 Narooie-Nejad et al.944606216494262214300/890/122 Al-Temaimi et al.3119081191528758420/290/42 Yamout et al.192386139324819112860/890/434 Cierny et al.9413838326214125123553732330/010/384 Luisa Agnello et al.3548211189023401286640/430/426 Terzi et al.3043141037148439137610/850/308 Abdollahzadeh et al.3880421561646368191941060/920/353 Yucel et al.13150411531261588560/050/388 Kamisli et al.7177192191155965221831090/550/373 Morales et al.65469176641224117285750/0050/208 Sadeghi et al.38411117431434262380/020/38 Cakina et al.2041981592045585550/0010/392 Křenek et al.11815127387205586611182880/190/325Study authorMS casesHealthy controlP-HWEMAFBBBbbbBbBBBbbbBBBsmI (rs1544410) Fukazawa et al.011661114332468301600/620/842 Qinli Sun et al.0756711901184111790/540/942 Bing Wu et al.0578516102694262140/180/891 Simon et al.39491312775344719115850/710/425 Sioka et al.28410974126550107550/0040/339 Al-Temaimi et al.20300703015251055450/940/45 Narooie-Nejad et al.5950416858456512155890/090/364 Abdollahzadeh et al.467935171149706515205950/980/316 Yamout et al.1021194159165330851130/350/57 Cierny et al.4313988225315731111192573490/0010/575 Luisa Agnello et al.2348339411417372171790/920/526 Terzi et al.1940287896144739751250/970/625 Morales et al.603822158821106010280800/630/222 Sadeghi et al.12511775851629561390/120/39 Cakina et al..143620647611372259810/480/578 Křenek et al.11415329381211616311185850/340/314Study authorMS casesHealthy controlP-HWEMAFAAAaaaAaAAAaaaAAApaI (rs7975232) Niino et al.212333658994145591310/930/689 Qinli Sun917373591152951591310/0050/689 Tajouri et al.355514125832354231001000/420/5 Smolders et al.58995521520980150593102680/450/463 Bing Wu et al.1439306799104565651750/580/729 Simon et al.29452610397285022106940/970/47 Irizar et al.39603513813076178863303500/370/514 Narooie-Nejad et al.4062111428461565178660/070/27 Al-Temaimi et al.20255653523171063370/050/37 Selma et al.1436106456405816138900/480/394 Yamout et al.192296040335115117810/510/503 Luisa Agnello et al.315815120882641893570/160/38 Abdollahzadeh et al.186775103217443103512490/840/83 Cierny et al.7813260288252102120813242820/0050/465 Terzi et al.28461310272424018124760/130/38 Yucel et al.8135292328371693690/550/425 Kamisli et al.6276292001345467251751170/590/4 Sadeghi et al.2253597632322568320/930/32 Cakina et al..282715835720212961790/0010/564 Křenek et al.27183862373553178261401300/070/481*P-HWE p*-value for Hardy--Weinberg equilibrium, *MAF* minor allele frequency of control group

Meta-analysis for FokI (rs2228570) polymorphism and MS {#Sec11}
------------------------------------------------------

Overall 16 case-control studies with 3057 cases and 2852 controls were analyzed for assessment of FokI gene polymorphism and MS risk. Of 16 studies, 9 studies carried out in Europe continent \[[@CR21], [@CR24], [@CR34]--[@CR40]\] 4 studies in Asia continent \[[@CR18], [@CR19], [@CR41], [@CR42]\] one study in America continent \[[@CR43]\] and finally 2 studies in Australia \[[@CR17], [@CR44]\] (Table [1](#Tab1){ref-type="table"}). No significant association was observed between FokI polymorphism and MS risk across all genetic models. Additionally, subgroup analysis based on geographical location was performed which the pooled results rejected any association between FokI polymorphism and risk of MS in European and Asian populations. Since there was only one study for American, and two studies for Australian populations, these studies were excluded from the subgroup analysis. The results of pooled ORs, heterogeneity tests and publication bias tests for different analysis models are shown in Table [3](#Tab3){ref-type="table"} **(**Additional file [1](#MOESM1){ref-type="media"}: Figures S1 and S2). Table 3Main results of pooled ORs in meta-analysis of Vitamin D Receptor Gene PolymorphismsSubgroupSample sizeTest of associationTest of heterogeneityTest of publication bias (Begg's test)Test of publication bias (Egger's test)Genetic modelCase/ControlOR95% CII^2^ (%)*P*Z*P*T*P*FokI (rs2228570) OverallDominant model3057 / 28521.060.94--1.1945.70.02−1.440.15−1.090.29Recessive model3057 / 28520.960.81--1.1323.80.140.780.450.130.90Allelic model3057 / 28521.080.93--1.2666.6≤0.0010.630.520.460.65ff vs. FF3057 / 28520.960.80--1.1648.40.010.050.96−0.630.54Ff vs.FF3057 / 28521.060.93--1.1926.40.16−1.440.15−1.330.20 EuropeanDominant model2480 / 22021.100.97--1.2641.70.08−1.160.24−0.620.55Recessive model2480 / 22020.960.80--1.1538.10.101.160.240.200.84Allelic model2480 / 22021.040.90--1.2056.50.010.270.78−0.320.75ff vs. FF2480 / 22021.000.75--1.3342.80.070.270.78−0.170.86Ff vs.FF2480 / 22021.110.97--1.2824.90.210.270.780.240.81 AsianDominant model243 / 2221.050.68--1.6170.90.03−0.520.60−0.860.54Recessive model243 / 2221.270.21--7.6157.90.12−10.31\*\*Allelic model243 / 2221.060.46--2.4580.9≤0.001−0.520.60−0.360.77ff vs. FF243 / 2220.510.02--14.1840.0110.31\*\*Ff vs. FF243 / 2220.930.60--1.4543.50.17−0.520.60−1.020.42TaqI (rs731236) OverallDominant model3758/39921.260.99--1.6080.5≤0.001−0.130.890.380.71Recessive model3758/39920.190.91--1.5763≤0.0011.750.081.460.16Allelic model3758/39921.160.94--1.4287.2≤0.001−0.870.380.240.81tt vs. TT3758/39921.260.93--1.7165.9≤0.0010.540.580.980.34Tt vs.TT3758/39921.27**1.01--1.59**74.5≤0.001−0.500.610.430.67 EuropeanDominant model2785 / 27061.110.99--1.2500.90−0.800.420.080.94Recessive model2785 / 27061.040.88--1.2300.631.170.241.140.27Allelic model2785 / 27061.060.97--1.1500.76−1.550.120.050.96tt vs. TT2785 / 27061.110.92--1.3300.820.630.520.980.34Tt vs.TT2785 / 27061.120.99--1.2700.79−0.720.47−0.080.94 AsianDominant model453 / 4711.530.34--6.9595≤0.001−0.980.32−0.240.82Recessive model453 / 4712.980.55--16.284.4≤0.001010.220.84Allelic model453 / 4711.430.40--5.1396.9≤0.001−1.960.05−0.590.59tt vs. TT453 / 4714.130.41--41.890.5≤0.001010.180.87Tt vs.TT453 / 4711.310.38--4.5491.7≤0.001−0.980.32−0.250.81BsmI(rs1544410)Dominant model1793 / 18150.840.48--1.4991.3≤0.001−0.240.801.810.09Recessive model1793 / 18151.300.92--1.8562.9≤0.0010.930.351.670.12Allelic model1793 / 18151.100.89--1.3769.7≤0.0010.180.850.230.82bb vs. BB1793 / 18151.240.78--1.9964.9≤0.001−1.950.05−0.550.59Bb vs.BB1793 / 18151.150.96--1.3749.60.02−1.460.14−1.650.12 EuropeanDominant model896 / 7640.620.25--1.5593.3≤0.001−0.190.851.500.2Recessive model896 / 7640.840.65--1.0900.661.470.141.840.16Allelic model896 / 7640.990.85--1.1600.51−0.940.34−1.450.22bb vs. BB896 / 7641.070.76--1.5000.46−1.960.05−1.290.28Bb vs.BB896 / 7641.080.72--1.6254.10.05−0.940.34−2.340.07 AsianDominant model676 / 7711.090.54--2.2278.5≤0.00101−0.300.78Recessive model676 / 7711.78**1.08--2.93**44.20.09−1.350.17−1.010.35Allelic model676 / 7711.280.81--2.0279≤0.001−0.490.690.260.80bb vs. BB676 / 7711.500.46--4.8876.3≤0.001−1.360.17−0.970.43Bb vs.BB676 / 7711.080.59--1.9666.90.01−0.490.62−0.120.91ApaI (rs7975232)Dominant model2306 / 26691.040.82--1.3158≤0.001−1.230.21−1.140.26Recessive model2306 / 26690.830.66--1.0551≤0.001−0.580.55−0.570.57Allelic model2306 / 26690.940.80--1.1068.2≤0.001−0.550.58−1.020.32aa vs. AA2306 / 26690.850.63--1.1655.1≤0.001−0.780.43−1.260.22Aa vs. AA2306 / 26691.200.88--1.6472.2≤0.001−0.970.33−0.640.53 EuropeanDominant model1366 / 15391.130.87--1.4749.80.04010.210.84Recessive model1366 / 15391.010.78--1.3338.70.11−0.420.67−0.490.64Allelic model1366 / 15391.050.88--1.2453.60.0201−0.560.59aa vs. AA1366 / 15391.110.76--1.6356.90.010.830.400.060.95Aa vs. AA1366 / 15391.410.86--2.3181.4≤0.0010.830.400.520.61 AsianDominant model676 / 8160.870.49--1.5370.9≤0.001−1.730.08−2.670.03Recessive model676 / 8160.61**0.42--0.89**40.40.110.990.320.640.54Allelic model676 / 8160.810.57--1.1576.1≤0.0011.370.170.690.51aa vs. AA676 / 8160.52**0.32--0.86**280.200.250.800.370.72Aa vs. AA676 / 8161.030.59--1.7964.5≤0.001−2.230.02−2.170.07The significant values are presented with boldface

Meta-analysis for TaqI (rs731236) polymorphism and MS {#Sec12}
-----------------------------------------------------

There were 23 case-control studies with 3758 cases and 3992 controls concerning TaqI polymorphism and MS risk. Among them, 13 studies were conducted in European countries \[[@CR21], [@CR22], [@CR24], [@CR34], [@CR36], [@CR37], [@CR39], [@CR40], [@CR45]--[@CR49]\], 5 studies in Asian countries \[[@CR18], [@CR41], [@CR42], [@CR50], [@CR51]\], 2 studies in each Australian \[[@CR17], [@CR44]\] and American \[[@CR43], [@CR52]\] countries, and one study in Tunisia \[[@CR20]\]. The TaqI polymorphism was demonstrated to be associated with MS risk under heterozygote contrast (OR = 1.27, 95%CI = 1.01--1.59, random effect) (Fig. [2](#Fig2){ref-type="fig"}), whilst no significant association was detected across other genotype models (Table [3](#Tab3){ref-type="table"}). In addition, the pooled results of subgroup analysis decline presence of significant association under all defined genetic model **(**Additional file [1](#MOESM1){ref-type="media"}: Figures S3 and S4). Groups with less than three studies were removed from subgroup analysis. The results of pooled ORs, heterogeneity tests and publication bias tests for different analysis models are shown in Table [3](#Tab3){ref-type="table"}. Fig. 2Pooled OR and 95% CI of individual studies and pooled data for the association between *TaqI* gene polymorphism and MS risk in Tt vs. TT Model (TaqI)

Meta-analysis for BsmI (rs1544410) polymorphism and MS {#Sec13}
------------------------------------------------------

After searching databases, finally 16 case-control studies with 1793 cases and 1815 controls subjects included to examine association between BsmI polymorphism and MS risk. Among 16 studies, six studies were performed in Europe \[[@CR21], [@CR22], [@CR36], [@CR40], [@CR48], [@CR49]\], eight studies in Asia \[[@CR18], [@CR41], [@CR50], [@CR51], [@CR53]--[@CR55]\], and only two studies in America continent \[[@CR43], [@CR52]\]. The pooled results demonstrate no significant association between BsmI polymorphism and MS risk under all genetic models, but subgroup analysis revealed that BsmI polymorphism across recessive model increased the risk of MS in Asian population (OR = 1.78, 95%CI = 1.01--2.93, random effect) compared to European population (OR = 0.84, 95%CI = 0.66--1.06, random effect) (Fig. [3](#Fig3){ref-type="fig"}). The results of pooled ORs, heterogeneity tests and publication bias tests for different analysis models are shown in Table [3](#Tab3){ref-type="table"} **(**Additional file [1](#MOESM1){ref-type="media"}: Figures S5 and S6). Fig. 3Pooled odds ratio (OR)) and 95% confidence interval of individual studies and pooled data for the association between *BsmI, ApaI* gene polymorphism and MS risk in different ethnicity subgroups and overall populations for A; Recessive Model (*ApaI*), B; aa vs. AA Model (*ApaI*), and C; Recessive Model *(BsmI*)

Meta-analysis for Apa1 (rs7975232) polymorphism and MS {#Sec14}
------------------------------------------------------

For quantitative synthesis of association between ApaI polymorphism and MS risk, 20 case-control studies with 2306 cases and 2669 controls were identified to be eligible. Overall, nine studies in Europe \[[@CR21], [@CR36], [@CR37], [@CR39], [@CR40], [@CR45], [@CR46], [@CR48], [@CR49]\], eight studies in Asia \[[@CR18], [@CR41], [@CR42], [@CR50], [@CR51], [@CR54]--[@CR56]\], and one study in Africa \[[@CR20]\], America \[[@CR43]\] and Australia \[[@CR17]\] were identified. There was no evidence of association between ApaI polymorphism and MS risk in the pooled results. However, subgroup analysis detected significant association between presence of ApaI SNP and risk of MS under recessive model (OR = 0.61, 95%CI = 0.42--0.89, random effect) and homozygote model (OR = 0.52, 95%CI = 0.32--0.86, random effect) in Asian population in comparison with European population (OR = 1.01, 95%CI = 0.78--1.33, recessive model) and (OR = 1.11, 95%CI = 0.76--1.63, homozygote model) (Fig. [3](#Fig3){ref-type="fig"}). The results of pooled ORs, heterogeneity tests, and publication bias tests for different analysis models are shown in Table [3](#Tab3){ref-type="table"} **(**Additional file [1](#MOESM1){ref-type="media"}: Figures S7 and S8).

Evaluation of heterogeneity {#Sec15}
---------------------------

Significant heterogeneity existed for FokI, TaqI, BsmI, and ApaI polymorphism in all of the genetic models. Furthermore, in subgroup analysis, there was a significant heterogeneity for studies carried out in Asian and European countries (Table [3](#Tab3){ref-type="table"}).

Publication bias and Sensitivity analysis {#Sec16}
-----------------------------------------

Publication bias was estimated using funnel plot, Begg's and Egger's tests. No evidence of publication bias was seen for all four SNP and subgroup analysis under all genetic models. Additionally, the shape of the funnel plot appeared to be symmetrical, indicating that there was no significant publication bias (Fig. [4](#Fig4){ref-type="fig"}).The impact of individual study on pooled OR was estimated by sequential omission of each studies which results showed that no individual study significantly affected the pooled ORs under any genetic models of the VDR SNPs (Fig. [5](#Fig5){ref-type="fig"}).  Fig. 4Begg's funnel plot for publication bias test. **a**; Dominant Model *FokI* .**b**; Dominant Model *TaqI*. **c**; Dominant Model *BsmI.* **d**; Dominant Model *ApaI*. Each point represents a separate study for the indicated association Fig. 5Sensitivity analysis in present meta-analysis investigates the single nucleotide polymorphisms of Vitamin D Receptor contribute to risk for multiple sclerosis susceptibility (A, FokI; B, TaqI; C, BsmI; D, ApaI)

Discussion {#Sec17}
==========

*VDR* gene, as a pleiotropic gene, has been shown to be associated with several diseases. In the previous studies, the relationship between VDR gene single nucleotide polymorphisms and autoimmune disorders was evaluated in several meta-analyses. The study of Feng et al. \[[@CR57]\]. described that TaqI or BsmI polymorphism in *VDR* gene was significantly connected with autoimmune thyroid diseases. Mao et al. \[[@CR58]\]. represented that the BsmI B allele may act as a risk factor for onset of systemic lupus erythematous (SLE) among Asians and overall populations and also the FokI FF genotype act as a potential risk factor for SLE predisposition in Asians. Furthermore, Tizaoui et al. \[[@CR59]\] showed that the *VDR* gene TaqI and FokI polymorphisms may increase the risk of Rheumatoid arthritis (RA) in European populations. And finally, Wang et al. \[[@CR60]\] reported that the ApaI and BsmI polymorphisms were related with elevated susceptibility to type 1 diabetes (T1D) in Asian populations. Collectively, it could be assumed that *VDR* gene polymorphisms act as a potential risk factor in development or progression of autoimmune disorders.

Although four meta-analyses have been conducted in the past 10 years to evaluate the relationship between the *VDR* gene polymorphisms and MS, these findings were inconclusive due to the variations of the literature and selected databases. Hence, for resolving these inconsistencies, and to decrease the heterogeneity and the probability of random errors, we set out an updated meta-analysis. In this study, 30 studies met the inclusion criteria and were included for quantitative synthesis. No evidence of publication bias was observed for all four SNP in subgroup analysis and overall populations under five genetic models. Regarding the essential role of genetic factors in the pathogenesis of MS, we categorized our results according to ethnicity. Our meta-analysis revealed that BsmI, ApaI, and TaqI polymorphisms may play a significant role in the pathogenesis of MS in overall and Asian population. The results of this study indicated that TaqI polymorphism was associated with MS susceptibility under heterozygote contrast in overall population.

Subgroup analysis based on continent rejected any association between *VDR* gene polymorphisms and the MS risk in European population. However, a significant association between BsmI and ApaI polymorphisms and MS susceptibility was detected in Asian population. BsmI polymorphism was associated with 64% increased risk of MS under recessive model in Asian populations. On the other hand, ApaI polymorphism was associated with 37.5 and 34.5% decreased risk of MS under recessive model and aa vs. AA model in Asian populations, respectively. The possible reason of the conflicting results among Asian, European, and overall population could be related to environmental factors the individuals exposed to and different genetic backgrounds, which may have disproportionate effects on MS risk.

These findings are inconsistent with the results of the Huang et al. \[[@CR23]\] and Garcia-Martin et al. \[[@CR24]\] studies. In the study of Huang et al.., 11 case-control studies with 2599 cases and 2816 controls were included for assessing the association between *VDR* gene polymorphisms and the MS susceptibility, but no significant association was found. Another study by Garcia-Martin et al. that analyzed ten studies with 2944 MS patients and 3166 healthy subjects, reported that TaqI and FokI polymorphisms were not associated with the MS risk. In accordance with our study, the study of Zhang et al. \[[@CR25]\]. and Tizaoui et al. \[[@CR26]\]. showed a significant association between *VDR* gene polymorphisms and the MS susceptibility. However, there are some obvious differences in the findings of these studies in comparison with our study. Meta-analysis of Tizaoui et al.. reported an association of the FokI FF and ApaI AA genotypes with an elevated susceptibility of MS in a total of 3300 MS patients and 3194 healthy subjects from 13 case-control studies. In contrast, our analysis, consisting of 20 case-control studies, showed that ApaI polymorphism was associated with decreased risk of MS in Asian populations. In addition, the study of Zhang et al. reported that the A allele was related with the onset of disease in Asian populations. Nevertheless, the sensitivity analysis, by removing the studies not in HWE, rejected any association between the A allele and risk of MS, which was dissimilar to the results of the non-sensitivity analysis. Moreover, they failed to find any association between TaqI, BsmI, and ApaI polymorphisms and MS susceptibility in overall populations, Asians, and Caucasians. The main reasons that *VDR* gene polymorphism plays a diverse function across different studies or in different ethnic populations may be due to the following hints. Firstly, in many cases, controls in included studies deviated from HWE. Secondly, the differences in the ethnic contextual characteristics of the patients may be an important factor for these variations. Thirdly, *VDR* SNPs were suggested to be related with the basal levels of 1,25(OH)2D3 and vitamin D structure and function \[[@CR61]\], which in turn could influence MS predisposition. Finally, MS is regarded to be a polygenic disorder, and therefore it is expected that various gene loci are interacted in the pathogenesis of MS.

Several epidemiological studies have strongly proposed that vitamin D insufficiency and sunshine contributes to MS risk in temperate countries. Vitamin D sufficiency and insufficiency could be a protective and risk factor, respectively, among many other factors, and may be constantly regulating the global MS susceptibility from the mother's pregnancy to adulthood. The main role of vitamin D in MS seems to be immunomodulatory, affecting the different groups of T and B cells in the general immune system, however, neurotrophic and neuroprotectant mechanisms could also be applied at the central nervous system (CNS) \[[@CR62], [@CR63]\]. Interestingly, in clinical setting, correction of hypovitaminosis D through recommending oral D3 supplements resulted in raises in 25(OH)D levels in serum, which were correlated with reductions in annualized relapse-rate (ARR) in relapsing-remitting MS (RRMS) \[[@CR64]\]. The disease activity is generally improved with higher 25(OH)D level. Rotstein et al.. reported that in MS patients under fingolimod (FTY) therapy, higher 25(OH)D level was related to longer survival for the combined endpoint and for relapses \[[@CR65]\]. A recent randomized clinical trial reveled a potential therapeutic effect of cholecalciferol in RRMS patients with low serum 25OHD level, which already treated with interferon beta-1a \[[@CR66]\]. Furthermore, comprehensive systematic review by Dörr et al.. based on many line of data, including preclinical investigations, association studies, epidemiologic data, and animal studies on vitamin D status and disease activity, implies that higher serum level of vitamin D are beneficial in terms of the susceptibility to MS as well as the further course of the disease in patients with established MS \[[@CR67]\]. In the earliest phase of disease, lower levels of 25-hydroxyvitamin D correlates with higher disease activity, however, lower 25(OH)D3 levels hardly affects patients in terms of clinical presentations, implying that low 25(OH)D3 concentrations are rather a susceptibility factor for than an outcome of MS; Since the bioavailable vitamin D concentration did not differ between the MS patients and healthy subjects, the main mechanism underlying the association of vitamin D and MS does not seem to be linked with decreased vitamin D bioavailability \[[@CR68]\]. Despite all that has been discussed, a meta-analysis by Zheng and colleagues reported that vitamin D had no therapeutic effect on ARR and Expanded Disability Status Scale (EDSS) score in the patients with MS \[[@CR69]\].

Permutations and combinations of common variants account as a predisposition factors in the etiology of several complex diseases. Variations of DNA sequence like SNPs exert modest biological impacts \[[@CR11]\]. Three polymorphisms of VDR gene, including TaqI, ApaI, and BsmI do not influence the structure of VDR protein. Their affect may be associated with alterations in translation efficiency and/or stability of the RNA. On the other hand, the FokI polymorphism has been related to changes in both transcriptional activity and VDR protein structure \[[@CR70]\]. The wild-type short transcript of FokI is related with the elevated transcriptional activity \[[@CR70]\]. One potential exception is differential effect of the FokI polymorphism on the immune system \[[@CR16]\]. Our data suggested that the ApaI polymorphism has a significant functional effect on MS. Furthermore, the TaqI polymorphism was associated with MS risk. However, some other factors that were not examined in the current meta-analysis might affect the TaqI expression. At this point, the expression and function of VDR in transactivating target genes are indicated by environment, genetics, and ethnicity due to its complex interactions \[[@CR71]\]. Thus far, three essential environmental risk factors for MS have been determined: vitamin D insufficiency, cigarette smoking, and Epstein--Barr virus infection \[[@CR72], [@CR73]\]. Moreover, sun exposure interacts with VDR gene functional variants in childhood to affect MS predisposition.

Some limitations of this meta-analysis should be considered. First, inaccessibility to the original data of the included studies restricted our further assessment of potential interactions, since the interactions between and even various polymorphic region of the same gene may affect the risk. Moreover, this study was solely focused on the articles published in the English language. We detected significant heterogeneity in all of the genetic models, which could be derived by various factors, such as variations in ethnicities. In the current study, ethnicities were Caucasians from Asians, Caucasians from Europe and Australia. Also, heterogeneity may be created by publication year of included studies, which extended between 1999 and 2018. There are several other possible reasons which may be regarded as a source of heterogeneity. Firstly, the criteria of MS diagnosis are inconsistent between studies. While some of them employed Poser's criteria, other studies used McDonald's criteria for MS diagnosis. Secondly, gender may act as a potential source for heterogeneity. Although both male and female subjects were enrolled in most studies, two studies were not sex-matched and one study only included women subjects \[[@CR35], [@CR43], [@CR45]\]. Thirdly, genotyping methods were not consistent. While half of the included studies used PCR-RFLP, approximately the other half employed TaqMan assay and one study used PCR-SPP. Fourthly, geographical and ethnic factors may also participate in heterogeneity, because studies with the same ethnic source were accompanied in various geographical regions.

The results from the studies examined in this met-analysis should be interpreted with cautious for some reasons. Our findings suggest that, to afford accurate estimates of the relation between VDR polymorphisms and MS risk, several factors should be regarded. Although there are many functional VDR polymorphisms in the promoter region of the VDR gene, only four SNPs in the VDR gene have been evaluated. The interaction of the *MHC* genes with *VDR* gene have been demonstrated to be important in MS \[[@CR74], [@CR75]\]. Remarkably, various environmental factors may interact with VDR polymorphisms to alter MS susceptibility. The current meta-analysis could not assess all interactions between VDR polymorphisms and study characteristics because of insufficient data from the original publications.

Conclusion {#Sec18}
==========

Taken all together, the current meta-analysis affords a comprehensive investigation of the available information for the association between the VDR polymorphisms and MS susceptibility. This meta-analysis of 30 case-control studies reveled a significant association between TaqI polymorphism and MS susceptibility. In subgroup analysis, BsmI polymorphism was associated with increased risk of MS in Asian populations. In addition, ApaI polymorphism was associated with decreased risk of MS in Asian populations. However, neither in overall population nor in subgroup analysis significant association between Fok1 (rs2228570) polymorphism and MS susceptibility was found. Future large-scale studies on gene--environment and gene--gene interactions are required to estimate related risk factors and assist early diagnosis of patients at high risk for MS.
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 {#Sec19}

**Additional file 1:Figure 1.** Forest plot of association between Fok1 gene Polymorphism and MS risk; Dominant model, Recessive model allelic model, ff VS. FF model, Ff vs FF model. **Figure 2.** Forest plot of pooled odds ratio (OR)) and 95% confidence interval of individual studies and pooled data for the association between Fok1 polymorphism and MS risk in different ethnicity subgroups and overall populations for Dominant model, Recessive model, allelic model, ff VS. FF model, Ff vs FF model. **Figure 3.** Forest plot of association between Taq1 gene Polymorphism and MS risk; Dominant model, Recessive model, allelic model, tt VS. TT model, Tt vs TT model. **Figure 4.** Forest plot of pooled odds ratio (OR)) and 95% confidence interval of individual studies and pooled data for the association between Taq1 polymorphism and MS risk in different ethnicity subgroups and overall populations for Dominant model, Recessive model, allelic model, tt vs TT model, Tt vs TT model. **Figure 5.** Forest plot of association between Bsm1 gene Polymorphism and MS risk; Dominant model, Recessive model, allelic model, bb VS. BB model, Bb vs BB model. **Figure 6.** Forest plot of pooled odds ratio (OR)) and 95% confidence interval of individual studies and pooled data for the association between Bsm1polymorphism and MS risk in different ethnicity subgroups and overall populations for Dominant model, Recessive model allelic model, bb VS. BB model, Bb vs BB model. **Figure 7.** Forest plot of association between Apa1 gene Polymorphism and MS risk; Dominant model, Recessive model, allelic model, aa VS. AA model, Aa vs AA model. **Figure 8.** Forest plot of pooled odds ratio (OR)) and 95% confidence interval of individual studies and pooled data for the association between Apa1 polymorphism and MS risk in different ethnicity subgroups and overall populations for Dominant model, Recessive model, allelic model, aa VS. AA model, Aa vs AA model.
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